Abstract
In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared. 176 patients were included, and 150 received treatment greater than 8 weeks and are evaluable for treatment response. The two groups did not differ with regard to prognostic factors. Response rate for the AG and MA groups were 34% and 31% respectively, with duration of response of 13.1 and 13.0 months. Stable disease was obtained in 33% and 35% respectively. No difference was observed in survival. Side effects occurred more frequently in the AG group (42%) than in the MA group (18%).
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Aminoglutethimide / adverse effects
-
Aminoglutethimide / therapeutic use*
-
Bone Neoplasms / drug therapy
-
Bone Neoplasms / mortality
-
Bone Neoplasms / secondary*
-
Breast Neoplasms / drug therapy*
-
Female
-
Follow-Up Studies
-
Humans
-
Megestrol / adverse effects
-
Megestrol / therapeutic use*
-
Middle Aged
-
Multicenter Studies as Topic
-
Neoplasm Metastasis
-
Neoplasm Recurrence, Local / drug therapy
-
Prospective Studies
-
Randomized Controlled Trials as Topic
-
Receptors, Estrogen / analysis
-
Receptors, Progesterone / analysis
-
Tamoxifen / therapeutic use
Substances
-
Receptors, Estrogen
-
Receptors, Progesterone
-
Tamoxifen
-
Aminoglutethimide
-
Megestrol